A pilot, open-label, randomized, comparative study of the antiviral efficacy of lopinavir/ritonavir single-drug regimen versus lopinavir/ritonavir in combination with lamivudine/zidovudine in antiretroviral naive patients
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Lamivudine/zidovudine (Primary) ; Lopinavir/ritonavir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms MONARK
- Sponsors Abbott Laboratories
- 01 Jul 2009 Results of resistance analysis published in Antimicrobial Agents and Chemotherapy.
- 02 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov
- 30 Jan 2008 Results have been published